| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Product revenue, net | $13.1M+29.8% | $10.1M+29.9% | $7.8M | — | — | — |
| Cost of sales | $6.6M-14.5% | $7.8M+63.8% | $4.7M | — | — | — |
| Research and development | $44.5M+11.3% | $40.0M-53.9% | $86.7M+5.8% | $81.9M+18.9% | $68.8M+90.4% | $36.2M |
| Selling, general and administrative | $87.7M+118.7% | $40.1M+15.4% | $34.8M+15.0% | $30.2M | — | — |
| Asset impairment charges | $59.0M | — | — | — | — | — |
| Total Operating Expenses | $138.8M-5.4% | $146.8M+16.4% | $126.1M+12.5% | $112.1M | — | — |
| Operating loss | -$125.7M+8.0% | -$136.7M-15.5% | -$118.4M-5.6% | -$112.1M-21.4% | -$92.3M-82.8% | -$50.5M |
| Grant income | $3.0M+16.1% | $2.6M | — | — | — | — |
| Gain on change in fair value of warrant liabilities | $6.2M | — | — | — | — | — |
| Loss on extinguishment of debt | -$2.1M | $0 | — | — | — | — |
| Interest income | $4.1M+18745.5% | $22K | — | $1.9M+7392.0% | $25K-47.9% | $48K |
| Interest expense | -$89K+92.8% | -$1.2M | — | — | — | — |
| Other expense, net | -$3.3M-280.0% | -$867K-150.3% | $1.7M | — | — | — |
| Net loss available to common stockholders | -$124.0M+4.6% | -$130.0M-11.5% | -$116.7M+0.2% | -$116.9M-26.6% | -$92.3M-76.9% | -$52.2M |
| Net loss to common stockholders per common share, basic | -$14570.00+91.7% | -$176600.00+98.8% | -$14720250.00-73464.5% | -$20010.00-147.0% | -$8100.00 | — |
| Net loss to common stockholders per common share, diluted | -$14570.00+91.7% | -$176600.00+98.8% | -$14720250.00-73464.5% | -$20010.00-147.0% | -$8100.00 | — |
| Weighted average common shares outstanding, basic | 8.51B+1055.9% | 736.3M+9191.3% | 7.9M-99.9% | 5.84B-48.7% | 11.39B | — |
| Weighted average common shares outstanding, diluted | 8.51B+1055.9% | 736.3M+9191.3% | 7.9M-99.9% | 5.84B-48.7% | 11.39B | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.